Quarterly ResultAug 5, 2026, 07:08 AM
EyePoint Q2 2026 Net Loss $94.5M; LUGANO Wet AMD Data Expected August
AI Summary
EyePoint, Inc. announced its second quarter 2026 financial results, reporting a net loss of $94.5 million and a significant decrease in total net revenue to $0.5 million. Operating expenses rose to $97.9 million, primarily due to ongoing Phase 3 clinical trials. Despite the financial downturn, the company provided positive updates on its clinical pipeline, with topline data for the LUGANO wet AMD trial expected in August 2026 and full enrollment completed for its DME trials. The company also appointed a new Chief Strategic Science Officer and maintains a cash runway into Q4 2027.
Key Highlights
- Reported a net loss of $94.5 million, or ($1.09) per share, for Q2 2026.
- Total net revenue for Q2 2026 was $0.5 million, down from $5.3 million in Q2 2025.
- Operating expenses increased to $97.9 million in Q2 2026 from $67.6 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $180 million as of June 30, 2026.
- Topline data from the LUGANO pivotal Phase 3 wet AMD clinical trial is expected in August 2026.
- Topline data from the LUCIA pivotal Phase 3 wet AMD clinical trial is anticipated in Q4 2026.
- Pivotal Phase 3 DME clinical trials (COMO and CAPRI) are fully enrolled, with topline data expected in Q4 2027.
- Appointed Tarek S. Hassan, M.D., as Chief Strategic Science Officer in July 2026.
Price Impact
More from EYPT